USA opens volunteer registry to test vaccine 1:02

. – German firm BioNTech is confident it will seek regulatory approval by the end of the year for a coronavirus vaccine, the company’s chief executive officer told The Wall Street Journal in an interview on Wednesday and published on Friday.
Dr. Ugur Sahin said that due to the spread of the virus, it could take about a decade for the world population to achieve immunity, even if multiple vaccines are available at the same time. BioNTech has partnered with Pfizer in the US to develop the vaccine.

MIRA: Volunteers wanted to receive experimental vaccine against covid-19 in the US

“I suppose we will only end this virus when more than 90% of the world population has immunity, either by infection or by a vaccine,” Sahin told the Journal.

Sahin added that the company could produce several hundred million doses before approval and more than 1 billion doses by the end of 2021.

This week BioNTech and Phizer announced that the developing covid-19 vaccine has yielded positive data in early tests.

Novavax wins contract to continue development of its covid-19 vaccine 1:27

The companies shared their preliminary findings on Wednesday in a preliminary document showing that participants in a Phase 1/2 study of the vaccine, called BNT162b1, responded to immunization and were found to be well tolerated. The Phase 1/2 study is ongoing and the data has not yet been published in a peer-reviewed medical journal.

Preliminary data will help researchers determine a dose level for the vaccine, then select which of its multiple candidate vaccines will advance to a larger Phase 2/3 global study, which could begin as early as this month, the researchers said. companies.